De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Corcept Therapeutics Beheer
Beheer criteriumcontroles 3/4
De CEO Corcept Therapeutics' is Joseph Belanoff, benoemd in Jan1999, heeft een ambtstermijn van 25.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 9.34M, bestaande uit 11.6% salaris en 88.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.89% van de aandelen van het bedrijf, ter waarde $ 139.87M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 23 jaar.
Belangrijke informatie
Joseph Belanoff
Algemeen directeur
US$9.3m
Totale compensatie
| Percentage CEO-salaris | 11.6% |
| Dienstverband CEO | 25.8yrs |
| Eigendom CEO | 2.9% |
| Management gemiddelde ambtstermijn | 3.9yrs |
| Gemiddelde ambtstermijn bestuur | 23yrs |
Recente managementupdates
Recent updates
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable
Sep 28
If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity
Sep 06Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)
Aug 01With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For
Apr 15We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit
Feb 22Corcept Therapeutics: Key Catalysts Ahead
Feb 19After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar
Dec 23Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price
Nov 07Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?
Jun 23Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)
Feb 16Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today
Jan 11Corcept Therapeutics starts phase 2 trial of its ALS treatment
Oct 11Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?
Sep 27Corcept extends distribution agreement for Cushing’s syndrome drug
Sep 23Corcept Therapeutics: A Status Check
Sep 06Corcept cut to Hold at Truist on balanced risk-reward setup
Aug 01Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$125m |
| Mar 31 2024 | n/a | n/a | US$117m |
| Dec 31 2023 | US$9m | US$1m | US$105m |
| Sep 30 2023 | n/a | n/a | US$91m |
| Jun 30 2023 | n/a | n/a | US$94m |
| Mar 31 2023 | n/a | n/a | US$94m |
| Dec 31 2022 | US$7m | US$896k | US$101m |
| Sep 30 2022 | n/a | n/a | US$117m |
| Jun 30 2022 | n/a | n/a | US$113m |
| Mar 31 2022 | n/a | n/a | US$112m |
| Dec 31 2021 | US$11m | US$844k | US$113m |
| Sep 30 2021 | n/a | n/a | US$106m |
| Jun 30 2021 | n/a | n/a | US$98m |
| Mar 31 2021 | n/a | n/a | US$99m |
| Dec 31 2020 | US$6m | US$770k | US$106m |
| Sep 30 2020 | n/a | n/a | US$109m |
| Jun 30 2020 | n/a | n/a | US$114m |
| Mar 31 2020 | n/a | n/a | US$106m |
| Dec 31 2019 | US$5m | US$708k | US$94m |
| Sep 30 2019 | n/a | n/a | US$87m |
| Jun 30 2019 | n/a | n/a | US$78m |
| Mar 31 2019 | n/a | n/a | US$76m |
| Dec 31 2018 | US$6m | US$680k | US$75m |
| Sep 30 2018 | n/a | n/a | US$152m |
| Jun 30 2018 | n/a | n/a | US$148m |
| Mar 31 2018 | n/a | n/a | US$142m |
| Dec 31 2017 | US$4m | US$647k | US$129m |
Compensatie versus markt: De totale vergoeding ($USD 9.34M ) Joseph } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.11M ).
Compensatie versus inkomsten: De vergoeding van Joseph is het afgelopen jaar met meer dan 20% gestegen.
CEO
Joseph Belanoff (67 yo)
25.8yrs
Tenure
US$9,337,734
Compensatie
Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 25.8yrs | US$9.34m | 2.89% $ 141.3m | |
| CFO & Treasurer | 3.6yrs | US$3.72m | 0.012% $ 585.2k | |
| President of Endocrinology | 8.5yrs | US$3.91m | 0.10% $ 4.9m | |
| Chief Development Officer | 3.2yrs | US$3.86m | 0.0056% $ 271.1k | |
| Chief Business Officer & Secretary | 10.8yrs | US$3.96m | 0.040% $ 1.9m | |
| Chief Accounting & Technology Officer | 4.3yrs | geen gegevens | 0.0095% $ 463.1k | |
| Chief Scientific Officer | 4.3yrs | US$3.11m | 0.11% $ 5.5m | |
| Chief Human Resources & Communications Officer | 3.3yrs | geen gegevens | geen gegevens | |
| President of Emerging Markets | less than a year | geen gegevens | geen gegevens | |
| President of Oncology | less than a year | geen gegevens | geen gegevens |
3.9yrs
Gemiddelde duur
53.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van CORT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 25.8yrs | US$9.34m | 2.89% $ 141.3m | |
| Independent Director | 25.8yrs | US$492.53k | 5.08% $ 248.3m | |
| Independent Director | 20.3yrs | US$509.03k | 1.26% $ 61.4m | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Chairman | 25.8yrs | US$1.26m | 2.12% $ 103.6m | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 4.6yrs | US$511.53k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 5.1yrs | US$488.53k | 0% $ 0 |
23.0yrs
Gemiddelde duur
68.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van CORT zijn ervaren en ervaren (gemiddelde ambtstermijn van 23 jaar).